Similar articles

• Natural killer cell activation after interferon administration in patients with metastatic renal cell carcinoma: an ultrastructural and immunohistochemical study.

  Toliou T, Stravoravdi P, Polyzonis M, Vakalikos J. Toliou T, et al. Eur Urol. 1996;29(2):252-6. Eur Urol. 1996. PMID: 8647158
• Effects of interleukin-2 treatment on CD1d-restricted natural killer T cells.

  Sandberg JK, Moll M. Sandberg JK, et al. Clin Cancer Res. 2007 Jul 15;13(14):4311; author reply 4311-2. doi: 10.1158/1078-0432.CCR-07-1267. Clin Cancer Res. 2007. PMID: 17634562 No abstract available.
• [Activity of natural killer (NK) cells and their stimulation in patients with hypernephroma].

  Hofmann R, Lehmer A, Reidel G. Hofmann R, et al. Helv Chir Acta. 1984 Oct;51(3-4):411-5. Helv Chir Acta. 1984. PMID: 6209242 German. No abstract available.
• Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.

  Curti BD. Curti BD. Expert Rev Anticancer Ther. 2006 Jun;6(6):905-9. doi: 10.1586/14737140.6.6.905. Expert Rev Anticancer Ther. 2006. PMID: 16761934 Review.
• Lymphocyte therapy of renal cell carcinoma.

  Dillman RO. Dillman RO. Expert Rev Anticancer Ther. 2005 Dec;5(6):1041-51. doi: 10.1586/14737140.5.6.1041. Expert Rev Anticancer Ther. 2005. PMID: 16336095 Review.